BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18086799)

  • 1. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
    Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
    J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
    Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
    J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
    Nogová L; Reineke T; Josting A; Müller-Hermelink HK; Eich HT; Behringer K; Müller RP; Diehl V; Engert A
    Eur J Haematol Suppl; 2005 Jul; (66):106-10. PubMed ID: 16007877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.
    Klimm B; Franklin J; Stein H; Eichenauer DA; Haverkamp H; Diehl V; Fuchs M; Borchmann P; Engert A
    J Clin Oncol; 2011 Oct; 29(29):3914-20. PubMed ID: 21911729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
    Mauz-Körholz C; Gorde-Grosjean S; Hasenclever D; Shankar A; Dörffel W; Wallace WH; Schellong G; Robert A; Körholz D; Oberlin O; Hall GW; Landman-Parker J
    Cancer; 2007 Jul; 110(1):179-85. PubMed ID: 17526010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
    Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
    J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.
    Engert A; Ballova V; Haverkamp H; Pfistner B; Josting A; Dühmke E; Müller-Hermelink K; Diehl V;
    J Clin Oncol; 2005 Aug; 23(22):5052-60. PubMed ID: 15955904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
    Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group.
    Eichenauer DA; Bredenfeld H; Haverkamp H; Müller H; Franklin J; Fuchs M; Borchmann P; Müller-Hermelink HK; Eich HT; Müller RP; Diehl V; Engert A
    J Clin Oncol; 2009 Dec; 27(36):6079-85. PubMed ID: 19901121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
    Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM
    J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
    Wirth A; Yuen K; Barton M; Roos D; Gogna K; Pratt G; Macleod C; Bydder S; Morgan G; Christie D
    Cancer; 2005 Sep; 104(6):1221-9. PubMed ID: 16094666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodular lymphocyte-predominant Hodgkin's lymphoma.
    Nogovà L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2006 Mar; 1(1):60-5. PubMed ID: 20425333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
    Klimm B; Reineke T; Haverkamp H; Behringer K; Eich HT; Josting A; Pfistner B; Diehl V; Engert A;
    J Clin Oncol; 2005 Nov; 23(31):8003-11. PubMed ID: 16204002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma.
    Bräuninger A; Wacker HH; Rajewsky K; Küppers R; Hansmann ML
    Cancer Res; 2003 Apr; 63(7):1644-51. PubMed ID: 12670918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology.
    Pellegrino B; Terrier-Lacombe MJ; Oberlin O; Leblanc T; Perel Y; Bertrand Y; Beard C; Edan C; Schmitt C; Plantaz D; Pacquement H; Vannier JP; Lambilliote C; Couillault G; Babin-Boilletot A; Thuret I; Demeocq F; Leverger G; Delsol G; Landman-Parker J;
    J Clin Oncol; 2003 Aug; 21(15):2948-52. PubMed ID: 12885814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
    Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
    Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.